Dana-Farber’s Breast Oncology Center shared a post on X:
“Check out the Breast Cancer Research Digest – a summary of last week’s publications from select high-impact journals (January 21st-26th, 2025).
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.
Authors: Lynce F, et al.
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Authors: Lowell L Hart, et al.
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.
Authors: Qiu X, et al.
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
Authors: Sherene Loi, et al.
Pembrolizumab and chemotherapy in high-risk, early- stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.
Authors: Fatima Cardoso, et al.
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Authors: DeMichele A, et al.
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.
Authors: Fresia Pareja, et al.
The Role of Race/Ethnicity on the Association between Neighborhood Deprivation and Breast Cancer Outcomes among Kentucky Breast Cancer Patients years 2010-2022.
Authors: Breyanna Walker, et al.
Obesity increases DNA damage in the breast epithelium.
Authors: Mohamed Gaber, et al.
Bone-Induced Her2 Promotes Secondary Metastasis in HR+/Her2- Breast Cancer.
Authors: Rahat Alam, et al.
Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors.
Authors: Edwin C Pratt, et al.
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Authors: Mohamed A Gouda, et al.
Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors.
Authors: Zhengyan Kan, et al.
Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial.
Authors: Christian Kurzeder, et al.
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers.
Authors: Lothar Häberle et al.
Natural killer cells occupy unique spatial neighborhoods in HER2(-) and HER2(+) human breast cancers.
Authors: Femke A I Ehlers, et al.
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.
Authors: Noor A M Bakker, et al.
Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery.
Authors: Astrid D Morris, et al.
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
Authors: Yutaka Yamamoto, et al.